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Rapidly evolving entities, such as viruses, can undergo complex
genetic changes in the face of strong selective pressure. We have
developed a modified heteroduplex tracking assay (HTA) capable
of detecting the presence of single, specific mutations or sets of
linked mutations. The initial application of this approach, termed
multiple-site-specific (MSS) HTA, was directed toward the detec-
tion of mutations in the HIV-1 pro gene at positions 46, 48, 54, 82,
84, and 90, which are associated with resistance to multiple
protease inhibitors. We demonstrate that MSS HTA is sensitive and
largely specific to all targeted mutations. The assay allows the
accurate and reproducible quantitation of viral subpopulations
comprising 3% or more of the total population. Furthermore, we
used MSS HTA in longitudinal studies of pro gene evolution in vitro
and in vivo. In the examples shown here, populations turned over
rapidly and more than one population was present frequently. To
demonstrate the versatility of MSS HTA, we also constructed a
probe sensitive to changes at positions 181 and 184 of the RT
coding domain. Changes at these positions are involved in resis-
tance to nevirapine and 2*,3*-dideoxy-3*-thiacytidine (3TC), respec-
tively. This assay easily detected the evolution of resistance to 3TC.
MSS HTA provides a rapid and sensitive approach for detecting the
presence of and quantifying complex mixtures of distinct geno-
types, including genetically linked mutations, and, as one example,
represents a useful tool for following the evolution of drug
resistance during failure of HIV-1 antiviral therapy.
One important example of the adaptive potential of HIV-1 isthe evolution of strains resistant to protease or reverse
transcriptase (RT) inhibitors. The population dynamics under-
lying the evolution of resistance are poorly understood, mostly
because of limitations imposed by the methods available. The
cloning and sequencing of PCR products from viral RNA or
proviral DNA is one approach that is used widely to study
changes in viral subpopulations. Although this method can yield
detailed data about the sequences present, it is labor intensive.
Moreover, the number of clones that are needed to determine
accurately the frequency of distinct sequence subpopulations is
large. A number of nonsequencing methods, such as the Line
Probe Assay (1), sequence-specific PCR (2), molecular beacons
(3), oligonucleotide ligation assays (4, 5), bulk sequencing (6), or
others (7, 8), can be used to determine genotypes and to estimate
the frequency of populations differing at defined positions.
Although these techniques are easier than sequencing multiple
clones, some have limited sensitivity, are only capable of detect-
ing individual mutations, or cannot establish the linkage of
detected mutations in the genome of a subpopulation.
The heteroduplex tracking assay (HTA) can be used to study
viral population dynamics. In this assay, a radioactively labeled
probe is annealed to a PCR product (derived from the total viral
population) to generate probe-PCR product heteroduplexes that
can be separated by gel electrophoresis. Clustered mutations,
insertions, or deletions result in altered migration of the het-
eroduplex, which can reveal distinct subpopulations of viral
genomes. HTA is quantitative, sensitive, simple, and allows the
inference of linkage between different mutations. The standard
HTA, because of its reliance on naturally occurring clustered
point mutations, insertions, and deletions to induce altered
heteroduplex migration, has been restricted largely to the inves-
tigation of the highly variable envelope region of HIV and other
viruses (9–12).
Here, we describe a multiple-site-specific (MSS) HTA that
allows the detection of multiple predefined point mutations. The
specificity for detecting point mutations is introduced into the
probe by changing nucleotides close to the sites of interest. This
is an application of the universal heteroduplex generator tech-
nology (13–15) but altered to detect viral subpopulations with
varyious numbers of specific mutations. We have generated a
probe capable of detecting mutations at positions 46, 48, 54, 82,
84, and 90 of the HIV-1 protease gene (pro). These six mutations
contribute to resistance to the HIV-1 protease inhibitors ritona-
vir, saquinavir, and indinavir (reviewed in ref. 16). We show
examples of the evolution of HIV-1 measured by MSS HTA
under the selective pressure of protease inhibitors in vitro and in
vivo. Finally, this strategy has been extended to detect mutations
in the HIV-1 DNA polymerase gene (pol) associated with
resistance to inhibitors of RT.
Materials and Methods
Patient Samples. Blood plasma samples were obtained—unlinked
to patient identifiers—as excess tissue samples with institutional
review board approval.
Plasmids and Probes. A 247-bp fragment of pro was amplified from
the HIV-1 molecular clone Hxb-2R with a wild-type pro se-
quence (17) by using PCR with primers PRAMPUP (59-
AACTAAAGGAAGCTCTATTAGATACAGGAG-39) and
PRAMPDW (59-GGAAAATTTAAAGTGCAACCAAT-
CTGA-39). The amplified product spanned codons 18–99 of pro.
The PCR product was cloned into pT7Blue (Novagen). The
plasmid pPR-EB was generated by moving the EcoRI in the
multiple cloning site closer to the inserted pro fragment for
improved labeling.
A 166-bp fragment of HIV-1 molecular clone Hxb-2r pol gene
spanning RT codon positions 150 through 205 was cloned into
pT7blue analogously (plasmid pRTWT). The fragment was ampli-
fied by using primers RTUP1 (59-CACAGGGATGGAAAGGAT-
CACCA-39) and RTDOWN1 (59-AGCTCCTCTATTTTTGTTC-
TATGCTGC-39).
Abbreviations: HIV-1, HIV type 1; MSS, multiple-site-specific; HTA, heteroduplex tracking
assay; RT, HIV-1 reverse transcriptase; 3TC, 29,39-dideoxy-39-thiacytidine.
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Site-Directed Mutagenesis. Site-directed mutagenesis was done as
described (18). The mutagenic primers used for the site-directed





Primers used in the site-directed mutagenesis of pRTWT were
pESA (59-ATACAAATCA{TA}{GCT}C{TA}T{GAT}TATT-
GATAGAT-39) and pESB (59-ATGCTTATAT{TC}G{GC}T-
{TCG}G{AT}TAACTATGTC-39). The Ns represent the inclu-
sion of all four nucleotides at that position in the oligonucleotide
synthesis, and the bracketed nucleotides represent the inclusion of
a subset of the bases at that position during synthesis.
Probe Labeling. A 10 mg aliquot of pPR-EB6.1 was digested with
EcoRI followed by the incorporation of [a-35S]dATP (0.1 mCi,
3000 mCiymmol) in a fill-in reaction using the Klenow fragment
of DNA polymerase I (10 units). After incubation for 15 min at
room temperature, the reaction was stopped by the addition of
EDTA and the enzymes were inactivated by heat. The probe was
released from the plasmid by NdeI digestion in the same mixture.
Unincorporated nucleotides were removed by column purifica-
tion over a MicroSpin G50 spin column (Amersham Pharmacia).
Plasmid pRT2.1 was labeled analogously, except that BamHI
was used for the first digestion and unlabeled dGTP was added
to the labeling reaction to fill in the first position in the 59
overhang.
Sequencing of Patient-Derived pro Clones. Separate RT-PCR prod-
ucts were generated to determine the pro sequences of clones
from patient 1005. The primers used (59-GGGCCATCCATTC-
CTGGC-39 and 59-CAGAGCCAACAGCCCCAC-39) amplify a
fragment from the gag p6 coding region to the 59 end of pol. The
RT-PCR products were cloned into pT7Blue as described pre-
viously and were sequenced by using dye-terminator chemistry.
Molecular clones were assigned to the bands found in the patient
by using HTA, and several clones were sequenced for each HTA
band except the lower band at month 9.
HTA. Heteroduplexes were generated in annealing buffer (100
mM NaCly10 mM TriszHCl, pH 7.5y2 mM EDTA) by denaturing
a mixture of 5 ml of PCR product and 0.1 mg of radioactively
labeled probe for 2 min at 95°C, followed by annealing during
cooling for 5 min at room temperature. The heteroduplexes were
subjected to 12% PAGE (acrylamide:bisacrylamide 5 61.5:1,
volyvol) in a GIBCOyBRL gel apparatus VP-16–2 at 15 mA per
gel in TBE gel buffer. After separation, the heteroduplexes were
visualized by autoradiography. Quantitative analysis was per-
formed with a Storm 840 phosphor imager by using the IMAGE-
QUANT software (Molecular Dynamics). When this assay was
done with two unlabeled PCR fragments, the heteroduplexes
were visualized by silver stain (Bio-Rad).
The mobility (k) of a heteroduplex was calculated as the
distance between the heteroduplex and the top of the gel divided
by the distance between the double-stranded probe and the top
of the gel.
RNA Isolation and RT-PCR. Viral RNA was isolated from 140 ml of
blood plasma by using the QIAmp Viral RNA kit (Qiagen,
Chatsworth, CA). For the pro fragment, reverse transcription
was carried out with the Titan One Tube RT-PCR System
(Roche Molecular Biochemicals) with the following modifica-
tions: RT reactions contained 5 ml of RNA solution, 13 Titan
RT-PCR buffer, 5.25 mM MgCl2, 0.5 mM of each dNTP, 5 mM
DTT, 2 mM primer PRAMPDW, 20 units of RNase inhibitor
(Roche Molecular Biochemicals), and 12.5 units of avian my-
eloblastosis virus RT (Roche Molecular Biochemicals) in a final
volume of 20 ml. Reactions were carried out at 42°C for 45 min
followed by heat inactivation. PCR mix (30 ml; 13 Titan
RT-PCR buffer, 5 mM DTT, 1.3 mM primer PRAMPUP, and
1 ml of Titan enzyme mix) was added. PCR was performed in a
Stratagene 40 Robocycler (1 cycle at 95°C for 3 min, 56°C for
60 s, and 68°C for 60 s; 40 cycles at 95°C for 40 s, 56°C for 60 s,
and 68°C for 60 s to 4 min). Extension times were increased by
1 min per 10 cycles from 60 s to 4 min.
The RT fragment was amplified analogously, except for a
lower Mg21 concentration of 1.5 mM during reverse transcrip-
tion and altered cycling conditions (1 cycle at 95°C for 3 min,
50°C for 60 s, and 68°C for 60 s; 40 cycles at 95°C for 45 s, 50°C
for 60 s, and 68°C for 60 s to 4 min).
DNA Isolation and Genomic PCR. HIV-1 cultures for in vitro selec-
tion of protease inhibitor resistance, genomic DNA isolation,
and PCR amplification for bulk sequencing were described (19).
PCR for MSS HTA was done by using the Expand High Fidelity
PCR System (Roche Molecular Biochemicals) with the following
modifications: reactions contained 0.2–4 mg of total cellular
DNA, 13 Titan RT-PCR buffer, 3 mM MgCl2, 0.2 mM of each
dNTP, 5 mM DTT, 0.5 mM primers PRAMPUP and
PRAMPDW, and 1 ml of Expand enzyme mix. Cycling condi-
tions were as described previously.
Drug Susceptibility Assay and Bulk Sequencing of pro. The bulk
sequence of pro was determined as described (20). Drug sus-
ceptibility of viral populations was measured by using a recom-
binant virus assay (20).
Results
Modification of an HTA Probe to Detect Multiple Point Mutations. An
MSS HTA probe that was sensitive to base changes at six
different positions in the subgroup B HIV-1 pro gene was
generated by multiple rounds of site-directed mutagenesis fol-
lowed by screens for appropriate mutations. To generate a probe
with sensitivity to a specific base change, libraries of mutant
clones with base changes in close proximity to the target
mutation were generated. Clones of this library were then
amplified and the PCR products were annealed to either wild-
type or mutant PCR products. The heteroduplexes were sepa-
rated by PAGE, and a clone with a differential mobility change
between wild-type and mutant PCR products was chosen. Sen-
sitivity to additional mutations was introduced by repeating the
mutagenesis-and-screening cycle. For the pro MSS probe 6.1, 12
bases were modified to achieve sensitivity to changes at six
positions (Fig. 1A). This probe, when radioactively labeled and
annealed to the sequences containing the targeted mutations,
displayed slower mobility in PAGE than the probe wild-type
heteroduplex (Fig. 1B). The presence of multiple mutations
resulted frequently in a change of the mobility of the heterodu-
plex when compared with single mutations. This observation
implies that the detection of multiple bands in a sample indicates
the presence of distinct genotypes that differ by sets of linked
mutations. In the absence of sequence information, the nature
of the linked sequences cannot be known but their presence is
inferred by the detection of distinct species.
MSS HTA Is Specific Largely for Changes in the Region of the Targeted
Positions. To assess the specificity of MSS HTA for the resis-
tance-relevant mutations, we tested the MSS probe 6.1 against
a panel of mutated protease-coding domains. This panel con-
tained clones with only single nucleotide changes and covered
most pro codons between positions 20 and 95 (21). The se-
quences were amplified from M13 phage stocks with mutated
HIV-1 pro-pol inserts, and the PCR products were subjected to
MSS HTA. The mobility of the heteroduplexes is shown graph-
ically in Fig. 2. Peaks representing heteroduplexes of decreased







mobility were found at all targeted positions. As would be
expected, some of the changes in codons adjacent to targeted
positions resulted in mobility shifts as well, reducing the speci-
ficity of the MSS HTA. This regional sensitivity can be seen with
substitutions encoding I47R, G49V, F53Y, F53V, and silent
mutations at positions 83 and 85, which resulted in mobility shifts
similar to those induced by the targeted mutations. However,
changes at more distal, nontargeted positions do not cause
significant mobility changes. In addition, only a total of 19 coding
changes in the 10 positions adjacent to the targeted positions
were found in 709 unrelated pro sequences from untreated
individuals retrieved from an HIV-1 protease database (22).
This low degree of variability in the flanking codons reduces the
impact of the regional sensitivity of the probe when assessing the
presence of resistance-associated mutations.
MSS HTA Allows the Accurate Quantitation of HIV-1 Populations. We
determined that the HTA band intensities were an accurate
reflection of the PCR mixture by creating mixtures of PCR
products amplified separately from different pro genes. Two
different mixtures were analyzed to demonstrate sequence in-
dependence of the assay. To generate both mixtures, a wild-type
PCR product was combined with a PCR product containing
either 8 or 12 mutations. We used a high number of changes to
confirm that the annealing reaction was not biased toward
sequences with fewer mismatches. The products were mixed at
various ratios and the mixtures were diluted over a 100-fold
range so that the subsequent annealing reaction would span
conditions from excess target to excess probe. The abundance of
the PCR products in the mixture was measured by MSS HTA and
showed a linear correlation with the known input abundance at
all dilutions (Fig. 3A). The best-fit line does not intersect the
origin, probably because of a small inaccuracy in the initial
determination of the concentration of PCR products. The linear
relation was independent of whether probe or target molecules
were in excess, and MSS HTA accurately quantified the minority
population down to 3% of the total. No input levels below 3%
were tested because the number of template molecules typically
available in clinical samples precluded the reproducible quan-
titation (i.e., sampling) of viral variants with lower than a 3%
frequency. Also, a species that represents 3% of the total
population is well above the background that becomes apparent
with longer exposure of the gel.
The question of PCR recombination was addressed by ampli-
fying mixtures of viral molecular clones. Products of recombi-
nation during PCR would be expected to shift differently from
either of the two parental sequences, and would therefore be
visible as a new band or as a smear between the two parental
bands. However, no such bands were detected in our recon-
struction experiments, indicating that recombination during
PCR does not significantly impact the results of MSS HTA (data
not shown).
To validate that a viral population was sampled correctly by
RT-PCR, the amplification reactions were replicated to compare
HTA patterns. Reproducible HTA patterns can be achieved only
if the population has been accurately sampled, because stochas-
tic events under conditions of limiting templates during PCR
would not allow the reproduction of HTA patterns if the
sampling of the viral population was incomplete. Reproducible
HTA patterns from clinical samples are typically observed with
as few as 2,000 RNA template molecules per reaction (data not
shown). Moreover, we amplified known mixtures of different pro
genes to examine the minimal number of DNA templates needed
for the accurate quantitation of a pro population comprising 10%
of the total (Fig. 3B). We found that 1,200 DNA template
molecules were sufficient to quantitate a subpopulation repre-
senting 10% of the total population reproducibly.
Correlation Between MSS HTA and Drug Susceptibility. MSS HTA
was performed on RT-PCR products derived from viral RNA
that was isolated from 21 patient plasma samples and correlated
with reduced sensitivity to HIV-1 protease inhibitors, as was
Fig. 1. Characteristics of the pro MSS HTA probe 6.1. (A) Sequence of the
probe (1) aligned to the Hxb-2r sequence (2) in the areas of the target
positions. Base changes leading to resistance are indicated above the wild-
type sequence (3). Resistance-relevant changes are in close proximity to probe
wild-type mismatches. (B) Mobility of the radioactively labeled probe an-
nealed to PCR products of pro genes with point mutations. Only the hetero-
duplexes (hd) and the probe that annealed to its fully complementary strand
(double-stranded probe, dsP) are shown. Lanes: 1, wild type; 2, M46I; 3, G48V;
4, I54T; 5, L63P; 6, V82T; 7, V82A; 8, I84V; 9, L90M; 10, G48VyV82T; and 11,
G48VyL90M. The mobility (k) of each hd relative to the dsP is indicated above
all lanes. Note that wild type and L63P, a nontargeted mutation, have identical
mobilities, whereas all of the targeted mutations display lower mobilities. The
mobilities of the hds are calculated relative to the dsP to control for differ-
ences in the gel or in the electric field between lanes and gels.
Fig. 2. Specificity of the pro MSS HTA probe. (A) Mobility (k) of a panel of pro
genes containing different point mutations annealed to the pro MSS probe
plotted against the codon position of the mutation. Resistance-relevant mu-
tations are denoted with (F), all other mutations with (E). The line represents
the average of all mutations tested except for the resistance-relevant posi-
tions (indicated) where only resistance-associated mutations were averaged.
This was necessary because in some cases, nonresistance mutations at these
positions had higher mobilities than resistance-associated mutations. The six
targeted mutations had the lowest mobilities. However, some mutations in
codons adjacent to resistance-relevant positions induce mobility changes as
well. The gel shows an example of five point mutations encoding the follow-
ing substitutions: lane 1, I47R; lane 2, G48V; lane 3, G48E; lane 4, G48A; and
lane 5, G49G.
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determined by a recombinant virus assay. The samples were
selected based on phenotypic evidence of resistance in pro-
tease inhibitor-experienced subjects. The average reduction in
susceptibility to ritonavir, indinavir, and saquinavir (ra) of viral
populations compared with the molecular clone NL4–3 was
correlated with the mobility (k) of the sample. Of the 21
subjects examined, 11 harbored multiple pro populations (Fig.
4A). In these cases the mobility ratio of the most abundant
population was used. The amino acid changes found in the bulk
sequence of the viral populations are shown in Fig. 4A as well.
To identify the baseline variability of k, seven samples from
protease inhibitor-naı̈ve patients were included in the analysis
and are shown in Fig. 4B together with the mobility of the
molecular clones NL4–3 and Hxb-2r. Unlike any of the 21
samples from the protease inhibitor-experienced patients,
seven of these nine controls had mobilities greater than 0.89
(Fig. 4B). In good agreement with the reduced probe mobility,
20 of the 21 protease inhibitor-experienced patients harbored
viral sequences that conferred a greater than 2.5-fold reduc-
tion of average drug susceptibility, and all viral populations
contained at least one of the mutations targeted by the MSS
HTA probe. Thus, the pro MSS HTA can readily detect the
presence of reduced susceptibility markers to the target pro-
tease inhibitors, but, as can be seen from Fig. 4B, the mobility
ratios do not show a clear linear correlation with the level of
susceptibility. The weak correlation between mobility and the
level of susceptibility may be ascribed to the absence of a strict
correlation between mobility change and the magnitude of
resistance conferred by individual mutations. Similarly, the
additive effects of multiple mutations on mobility and resis-
tance are not likely to be strictly correlated. In addition,
mobility can be affected by mutations in positions adjacent to
the resistance mutations. Finally, any combination of muta-
tions not targeted by the probe, or outside the region covered
by the probe that would contribute to a resistance phenotype,
would go undetected. These complicating factors limit the
utility of MSS HTA in identifying complex patterns of pro
resistance mutations in a cross-sectional analysis. The useful-
ness of MSS HTA for longitudinal studies, however, is affected
less, because the main focus of longitudinal studies is the
emergence of new viral variants rather than the exact corre-
lation of the mobility ratio of specific variants with their
phenotype. Note that in this type of analysis, MSS HTA
complements and focuses the more labor-intensive approach
of sequence determination.
Fig. 3. Reproducibility and sensitivity of the pro MSS HTA. (A) The MSS HTA
reflects the populations in the PCR product accurately and reproducibly at
high template numbers. PCR products of two pro genes were mixed at known
ratios; the mixtures were then diluted over a 100-fold range and annealed to
the MSS HTA probe 6.1. The abundance of one of the products was deter-
mined by using the MSS HTA and compared with the known abundance. Error
bars represent standard deviations from 5–9 experiments. (B) Amplification of
pro gene mixtures. Mixtures of pro genes were amplified and quantified by
using the MSS HTA. The smallest number of templates required to detect and
quantify a 10% population reproducibly is 1,200. Error bars are the standard
deviation from three experiments. The sequences used encoded the following
changes from Hxb: (1) T12S, K43R, M46I, Q61L, L63P, V82A; (2) T12S, K43R,
M46I, I54V, Q61H, L63P, V82F.
Fig. 4. Cross-sectional study of viral pro populations and correlation of MSS
HTA mobility shifts with reduced drug susceptibility. (A) The MSS HTA analysis
of RT-PCR products from 21 patient plasma samples with different treatment
histories. Differences in the bulk sequence of the RT-PCR products from HIV-1
clade B consensus are shown above the gel. Two amino acids indicate a mixed
population. Note that positions that were not resistance-associated were
omitted. Note also that each population contains at least one of the targeted
mutations of the MSS HTA probe (highlighted in gray). In 11y21 cases, multiple
populations differing at or near the targeted positions were found by HTA,
whereas population-based sequencing identified mixed populations in only 4
subjects. hd, heteroduplex; dsP, double-stranded probe. (B) Mobility (k) of the
most prominent MSS HTA band of each subject correlated with the average
reduction of susceptibility to ritonavir, saquinavir, and indinavir (ra) of the
complete virus population compared with molecular clone NL4–3 (E). The
labels indicate the number of targeted mutations seen in the bulk sequence.
For comparison, the mobility of bands corresponding to viral populations
from seven protease inhibitor-naı̈ve patients (e) and the mobility of molec-
ular clones NL4–3 and Hxb-2r (r) are shown. Not all of these are visible on the
plot, because some mobilities are identical.







Longitudinal Studies of HIV-1 Evolution in Vitro and in Vivo by Using
MSS HTA. MSS HTA was applied to viral populations in cell
culture during passage with increasing selective pressure from
saquinavir (Fig. 5A). The selection gave rise to sequence changes
that were detected as HTA bands with slower migration. The
evolution of resistance appears to be a stepwise process in the
selected cultures with several populations coexisting at multiple
times. Sequence analysis confirmed that the observed mobility
changes coincided with the accumulation of resistance mutations
(Fig. 5A). This experiment also demonstrates that the MSS HTA
resolves different mixtures of linked mutations. Similar results
were obtained when selections were carried out with other
protease inhibitors (T.W. and R.S., unpublished observation).
MSS HTA was also able to separate viral populations present
in vivo and the populations could be followed over time. As an
example, we examined plasma samples from an HIV-1-infected
subject who participated in a ritonavir clinical trial (23). When
ritonavir was added to this subject’s existing RT inhibitor
therapy, viral load decreased by approximately 100-fold, re-
bounded within 3 months to pretreatment levels, and remained
stable for 6 months in the continued presence of ritonavir. As
shown in Fig. 5B, the pro variants in this subject’s blood plasma,
when represented as MSS HTA bands, shifted to successively
higher positions over time. At the start of ritonavir therapy (St),
the rebound (Re), and the end (E), there were two pro sequences
present. Again, sequence analysis confirmed that the changing
mobility of the bands was caused by resistance mutations (Fig.
5B). In addition, a change of all 3 nucleotides of codon 63 (L63C)
contributed to the mobility shifts. A similar pattern was observed
for 11 of the 12 patients who were studied during this trial (W.R.
and R.S., unpublished observation).
Adaptation of MSS HTA to pol Mutations Associated with Resistance
to RT Inhibitors. An MSS HTA can be developed rapidly for
different target sequences. As an example, we generated an MSS
HTA probe that targets nucleotide changes at positions 181 and
184 of the RT coding domain pol. Changes at these positions
have been shown to confer resistance to nevirapine and 29,39-
dideoxy-39-thiacytidine (3TC), respectively (24, 25). The RT
MSS probe 2.1 spans codons 150 through 205 of the RT coding
domain and contains 6 nucleotide changes (Fig. 6A). It shows
differential sensitivity to the three targeted mutations in the two
positions (Fig. 6B). This probe was applied to investigate the
evolution of resistance to 3TC in an individual. Rapid turnover
of populations after the addition of 3TC to the existing drug
regimen on day 215 is evident (Fig. 6B). Sequence analysis
confirmed that the observed mobility shift correlated with the
emergence of a base change at position 184.
Discussion
The protease and RT MSS HTAs introduced here represent an
improvement over the different techniques used up to this point
for the investigation into the population dynamics of viral
genotypes. This assay is distinct from the regular HTA because
of its sensitivity to single base changes and the partial selectivity
for predefined mutations. Although this selectivity is desirable,
it also limits the MSS HTA to systems with known mutations. In
contrast to the universal heteroduplex generator probes de-
scribed previously, which were designed to detect single point
mutations, MSS probes can detect multiple mutations in a
genome, and the presence of multiple linked mutations in a
single genome typically reduces further the migration in the gel
over single point mutations. This feature of HTA allows the
resolution of populations that differ by the number of mutations.
Moreover, compared with other assays used in population
dynamics, such as single-strand conformational polymorphism
and sequencing of clones, MSS HTA is simpler and does not
require specialized equipment. The longer initial setup time of
MSS HTA, compared with the sequencing of clones, is recovered
by the rapid analysis of large numbers of samples. Even though
the MSS HTA cannot completely obviate sequencing methods,
it can serve to focus sequencing efforts to a subset of relevant
Fig. 5. Longitudinal study of viral pro subpopulations under the selective
pressure of protease inhibitors in vitro and in vivo. (A) The MSS HTA of nine
different passages of a virus culture that was subjected to increasing concen-
trations of saquinavir. The stepwise shift of the MSS HTA bands to higher
positions can be seen and this shift correlates with an increasing number of
resistance mutations seen in bulk sequences derived from proviral DNA.
Positions highlighted in gray are target positions of the MSS probe. Two amino
acids indicate a mixed population. hd, heteroduplex; dsP, double-stranded
probe. (B) Patient 1005 was followed during a trial of ritonavir from the start
of monotherapy (St, day 1), through to the first timepoint of rebound of viral
RNA after initial response (Re, day 114), to the endpoint of the trial (E, day
228). The pro sequences of molecular clones corresponding to different
populations are indicated (L, lower band; U, upper band). Again, the target
positions of the MSS HTA probe are highlighted in gray. Note that the L63C
mutation represents a change of three nucleotides (CTC to TGT) which likely
leads to a mobility shift.
Fig. 6. Development of an RT MSS HTA. (A) Sequence of the RT MSS HTA
probe 2.1 (1) aligned to Hxb-2r wild-type sequence; (2) base changes involved
in resistance (3) are shown above. (B) Mobility of the radioactively labeled
probe when annealed to three PCR products containing resistance mutations
in comparison with the mobility of wild type (wt). In addition, plasma RNA of
Patient 1029 who started 3TC therapy at day 215 was subjected to an MSS HTA
analysis shown on the same gel. hd, heteroduplex; dsP, double-stranded
probe.
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samples while providing accurate information about the fre-
quencies of different genotypic species within the viral popula-
tion. The ability of MSS HTA to resolve discrete complex
genotypic species distinguishes it from other simple assays, such
as the line probe assay, PCR-based assays, or bulk sequencing.
The sensitivity of the pro probe is largely restricted to the
targeted mutations. Mutations in neighboring positions, how-
ever, can cause fortuitous mobility shifts (Fig. 2). We do not
expect this to be a major pitfall, because most of the adjacent
positions in pro appear to be conserved in a set of unrelated pro
sequences retrieved from a sequence database (22). The narrow
sensitivity distribution allows the selective detection of resis-
tance-relevant mutations without significant interference from
background mutations.
The heteroduplex of the pro probe and the wild-type pro PCR
product has a mobility of 0.90 because of the design of the MSS
HTA probe. The lowest observed mobility for the pro HTA in
this study was 0.73. Because bands with mobilities differing by
0.01 are resolved, we theorize that up to 18 populations could be
resolved in a single sample. As the number of possible combi-
nations of the six target mutations exceeds the theoretical
resolution, it is impossible to assign a single genotype to each
band. For this and other reasons discussed earlier, the MSS HTA
correlates with the phenotype of viral populations only in the
sense that there is a correlation between a greater than 2.5-fold
reduction in sensitivity in the presence of at least one of the
targeted mutations and a reduced mobility ratio (Fig. 4). The
inability to assign a specific genotype to MSS HTA bands, and
the imperfection of the correlation between HTA shift and
phenotypic drug susceptibility, would seem to limit the useful-
ness of MSS HTA for cross-sectional analyses of pro evolution.
In longitudinal studies, the aforementioned shortcomings of
the assay are less important because a change in the mobility
of bands relative to the populations at baseline is measured
over time rather than the absolute mobility of bands at a given
time. We applied the pro and the RT MSS HTA to longitudinal
samples to illustrate the behavior of the assays. In the case of
pro, we showed the stepwise accumulation of resistance mu-
tations in the viral populations correlating with successively
slower-migrating HTA bands in vitro and in vivo. Moreover, it
was observed that several populations frequently coexisted
and that the turnover of viral populations was rapid. Similar
results were obtained for the RT MSS HTA in vivo. Specifi-
cally, we saw the emergence of resistance to 3TC 40 days after
therapy start.
The data presented here suggest that the MSS HTA will be a
useful tool for the investigation of population dynamics. We can
take advantage of this technology to investigate not only popu-
lation dynamics in vivo, but also viral fitness in competition
cultures in vitro. In addition, the capabilities of both the pro and
RT probes can be expanded. The technology described here can
be deployed likewise to investigate sequence evolution in other
regions of HIV-1 and in other organisms. Possible examples
include the evolution of the human ras gene in oncogenesis or
bacterial genes involved in pathogenesis or resistance.
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